Collegium Pharmaceutical, Inc: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Feb 24, 2022 and accepted by EDGAR at Feb 24, 2022, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-10-01 to 2021-12-31 | $27.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2021-01-01 to 2021-12-31 | $276.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-10-01 to 2021-12-31 | $28.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $126.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-10-01 to 2021-12-31 | −$1.3m | us-gaap:GrossProfit |
| Gross profit | 12 months2021-01-01 to 2021-12-31 | $150.6m | us-gaap:GrossProfit |
| Research and development | 3 months2021-10-01 to 2021-12-31 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $9.5m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2021-10-01 to 2021-12-31 | $26.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2021-01-01 to 2021-12-31 | $119.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-10-01 to 2021-12-31 | −$34.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2021-01-01 to 2021-12-31 | $17.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-10-01 to 2021-12-31 | $4.8m | us-gaap:InterestExpense |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $21.0m | us-gaap:InterestExpense |
| Income tax | 3 months2021-10-01 to 2021-12-31 | −$13.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2021-01-01 to 2021-12-31 | −$74.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-10-01 to 2021-12-31 | −$25.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2021-01-01 to 2021-12-31 | $71.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-10-01 to 2021-12-31 | −$0.73 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | $1.86 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-10-01 to 2021-12-31 | −$0.73 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | $2.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-10-01 to 2021-12-31 | 34,123,309 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 41,045,805 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | $103.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $47.9m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $186.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $315.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $692.1m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $279.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $489.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $202.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-22-001927. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.